Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 6/20 | 0.52 |
| ▸ | CDK9 | P50750 | 6/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | QDPR | P09417 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | TNKS | O95271 | 1/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7549123 | 0.86 | MAPT (0.49) | CCNT1CDK9MAPTQDPRPPARG | |
| SCHEMBL20993990 | 0.84 | MAPT (0.50) | CCNT1CDK9MAPTQDPRMEN1 | |
| SCHEMBL4859866 | 0.79 | PDK4 (0.67) | CNR1JAK1PDK4 | |
| SCHEMBL29580432 | 0.79 | PDK4 (0.67) | CNR1JAK1PDK4 | |
| SCHEMBL27886023 | 0.78 | MEN1 (0.71) | MAPTMEN1KMT2ATDP1KCNH2 | |
| SCHEMBL11092802 | 0.78 | MAPT (0.45) | CCNT1CDK9MAPTQDPRPPARG | |
| SCHEMBL7396701 | 0.78 | KMT2A (0.46) | CCNT1CDK9MEN1KMT2ATDP1 | |
| SCHEMBL13801237 | 0.74 | TNKS (0.51) | CCNT1CDK9MAPTPPARGPPARA | |
| SCHEMBL28727024 | 0.74 | MAPT (0.44) | CCNT1CDK9MAPTQDPRMEN1 | |
| SCHEMBL10852905 | 0.74 | MAPT (0.55) | CCNT1CDK9MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8519143-B2 | Derivatives of (bridged piperazinyl)-1-alkanone and use thereof as p75 inhibitors | SANOFI (FR) | 2013-08-27 | — | — | US | claimed |
| US-20120289518-A1 | DERIVATIVES OF 2-OXOALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI (FR) | 2012-11-15 | — | — | US | claimed |
| US-20120245150-A1 | NOVEL (HETEROCYCLE/TETRAHYDROPYRIDINE)-(PIPERAZINYL)-1-ALCANONE AND (HETEROCYCLE/DIHYDROPYRROLIDINE)-(PIPERAZINYL)-1-ALCANONE DERIVATIVES, AND USE THEREOF AS p75 INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | claimed |
| US-20120232280-A1 | DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALKANONE AND USE THEREOF AS p75 INHIBITORS | SANOFI-AVENTIS (FR) | 2012-09-13 | — | — | US | claimed |
| WO-2011144835-A3 | TUBULAR PHOTOVOLTAIC DEVICE FOR PRODUCING ELECTRICAL ENERGY | THEROND PATRICK (FR) | 2012-05-10 | — | — | WO | claimed |
| EP-2297148-B1 | NOVEL DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALCANONE AND USE THEREOF AS P75 INHIBITORS | SANOFI SA (FR) | 2012-01-04 | — | — | EP | claimed |
| EP-2310383-B1 | DERIVATIVES OF 2-OXO-ALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI SA (FR) | 2011-11-30 | — | — | EP | claimed |
| US-20110144122-A1 | DERIVATIVES OF 2-OXOALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | claimed |
| US-20110144116-A1 | DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALKANONE AND USE THEREOF AS p75 INHIBITORS | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144122-A1 | DERIVATIVES OF 2-OXOALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | PKD2, OPRM1, DHFR | CCNT1 2181/4885CDK9 4704/4885MAPT 3573/4885 |
| US-20110144116-A1 | DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALKANONE AND USE THEREOF AS p75 INHIBITORS | NGF, NTRK2, NTRK3 | CCNT1 2587/4885CDK9 2430/4885MAPT 1393/4885 |
| US-20120245150-A1 | NOVEL (HETEROCYCLE/TETRAHYDROPYRIDINE)-(PIPERAZINYL)-1-ALCANONE AND (HETEROCYCLE/DIHYDROPYRROLIDINE)-(PIPERAZINYL)-1-ALCANONE DERIVATIVES, AND USE THEREOF AS p75 INHIBITORS | NTRK2, NTRK1, NTRK3 | CCNT1 808/4885CDK9 855/4885MAPT 3633/4885 |
| US-20120232280-A1 | DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALKANONE AND USE THEREOF AS p75 INHIBITORS | NGF, NTRK2, NTRK3 | CCNT1 2587/4885CDK9 2430/4885MAPT 1393/4885 |
| US-20120289518-A1 | DERIVATIVES OF 2-OXOALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | PKD2, OPRM1, DHFR | CCNT1 2181/4885CDK9 4704/4885MAPT 3573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.